How much would you pay to add 10 years to your heart?
20 million patients * $10,000 = $200 BILLION
This is a CONSERVATIVE estimate, IMO. Fresh supplies of Revascor will soon be on hand at every hospital in the world. Initial adopters will be paying much more than $10K per shot. And there will be more than 1 million new patients every year!
In the United States alone, congestive heart failure has an annual incidence of 670,000 patients, a prevalence of 6.2 million patients, and causes over 1.1. million hospitalizations and 300,000 deaths per year. Heart failure affects around 10 million in Europe and as many as 20 million worldwide.
Revascor (allogenic mesenchymal cells) PII results: - Reduced SEVERE adverse cardiac events from 93.3% to 44.4%. - Reduced MAJOR adverse cardiac events (cardiac death, heart attack, or coronary revascularization procedures) from 40% to 6.7% - Reduced DEATH from cardiac causes from 13.3% to 0%
Three-tiered approach to value creation 1. Near-term revenues - approved patient-specific products for elite athletes and high-net worth individuals 2. Mid-term value drivers underpinning capital growth - “off the shelf” products for major unmet medical needs 3. Long-term sustainability - R&D product pipeline
Our first-rate clinical results, together with completion of this strategic alliance, underscore Mesoblast's position as the world's leading stem cell and regnerative medicine company. Mesoblast will now have a market capitalization of approximately $1.5 billion, $280 million cash on hand...
This strategic alliance has the potential to transform Cephalon into one of the world's leading biopharmaceutical companies in the cardiovascular space. With Cephalon as a partner, we are uniquely equipped to develop additional therapeutics for a range of neurological conditions.
Will CEPH be able to fend off a hostile takeover? Their current market cap is only 4 billion and with their other products alone, they are still vastly undervalued at this price.
A single injection of Revascor at one of three progressively increasing doses has been administered to 45 patients randomized to receive cell therapy in addition to standard of care, while 15 control patients have been concomitantly randomized to receive standard of care alone, the companies said. The trial will be completed when all available patients have been followed up for 12 months.
Moreover, a single injection of Revascor reduced the overall monthly event rate of a MACE by 84 percent compared with controls (p = 0.01), and every dose tested demonstrated a similar protective effect, they said. Death from cardiac causes was reduced from 13.3 percent to zero over the period (p = 0.059) and the overall monthly rate of cardiac-related hospitalizations was reduced by 48 percent (p = 0.07).